These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9074895)

  • 1. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
    Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
    Frank D; Jaehde U; Fuhr U
    Eur J Clin Pharmacol; 2007 Apr; 63(4):321-33. PubMed ID: 17273835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
    Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
    Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
    Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
    Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
    J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB; Boeve TJ; Hande KR
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
    Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
    Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
    Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
    Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
    Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
    Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
    Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.